ATE270284T1 - Cholesterin esterase inhibitoren - Google Patents

Cholesterin esterase inhibitoren

Info

Publication number
ATE270284T1
ATE270284T1 AT03006153T AT03006153T ATE270284T1 AT E270284 T1 ATE270284 T1 AT E270284T1 AT 03006153 T AT03006153 T AT 03006153T AT 03006153 T AT03006153 T AT 03006153T AT E270284 T1 ATE270284 T1 AT E270284T1
Authority
AT
Austria
Prior art keywords
cholesterol esterase
esterase inhibitors
inhibitors
cholesterol
present
Prior art date
Application number
AT03006153T
Other languages
English (en)
Inventor
Lorraine Deck
Jagt David L Vander
Original Assignee
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Mexico filed Critical Univ New Mexico
Application granted granted Critical
Publication of ATE270284T1 publication Critical patent/ATE270284T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03006153T 1997-04-16 1998-04-15 Cholesterin esterase inhibitoren ATE270284T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4198897P 1997-04-16 1997-04-16

Publications (1)

Publication Number Publication Date
ATE270284T1 true ATE270284T1 (de) 2004-07-15

Family

ID=21919442

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98918098T ATE253565T1 (de) 1997-04-16 1998-04-15 Inhibitoren der cholesterolesterase
AT03006153T ATE270284T1 (de) 1997-04-16 1998-04-15 Cholesterin esterase inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98918098T ATE253565T1 (de) 1997-04-16 1998-04-15 Inhibitoren der cholesterolesterase

Country Status (7)

Country Link
US (3) US5942631A (de)
EP (1) EP0975617B1 (de)
JP (1) JP2002512611A (de)
AT (2) ATE253565T1 (de)
CA (1) CA2284525A1 (de)
DE (2) DE69824901D1 (de)
WO (1) WO1998046585A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20100324075A1 (en) * 2007-12-21 2010-12-23 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors
US9061796B2 (en) * 2009-04-23 2015-06-23 H.J. Heinz Company Multi-function condiment container
EP2844303B1 (de) 2012-05-03 2021-09-15 Beth Israel Deaconess Medical Center, Inc. Lipide zur erhöhung der insulinempfindlichkeit und verfahren zur verwendung davon
US10604473B2 (en) 2013-03-15 2020-03-31 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056802A (en) * 1960-10-04 1962-10-02 Union Carbide Corp Alpha-halo lactones
US3227736A (en) * 1962-10-31 1966-01-04 Olin Mathieson Production of alpha-fluorocarboxylic acids and esters
US3346594A (en) * 1965-08-25 1967-10-10 Gen Aniline & Film Corp Haloalkyl and polyhaloalkyl lactones
US4338122A (en) * 1979-09-26 1982-07-06 Union Carbide Corporation Biocidal 2-aryl-1,3-cyclopentanedione compounds and alkali metal and ammonium salts thereof
GB2168696B (en) * 1984-12-21 1989-01-11 Boehringer Biochemia Srl Fluoro coumarins as antilymphoedema agents
US5025017A (en) * 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5059696A (en) * 1990-03-15 1991-10-22 Merck & Co., Inc. Processes and intermediates for the preparation of 5-oxygenated hmg-coa reductase inhibitors
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
US5464824A (en) * 1992-11-18 1995-11-07 Firmenich Sa Use of furanones as perfuming ingredients
FR2741620B1 (fr) * 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline

Also Published As

Publication number Publication date
US6114545A (en) 2000-09-05
EP0975617A4 (de) 2000-09-13
EP0975617A1 (de) 2000-02-02
DE69824901D1 (de) 2004-08-05
JP2002512611A (ja) 2002-04-23
WO1998046585A1 (en) 1998-10-22
US6034255A (en) 2000-03-07
CA2284525A1 (en) 1998-10-22
EP0975617B1 (de) 2003-11-05
US5942631A (en) 1999-08-24
ATE253565T1 (de) 2003-11-15
DE69819482T2 (de) 2004-08-26
DE69819482D1 (de) 2003-12-11

Similar Documents

Publication Publication Date Title
IS2148B (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem COX-2 hindrar
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
PT927161E (pt) Aminas ciclicas substituidas inibidoras de metaloproteases
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
PT966465E (pt) Inibidores do enzima imfdh
YU35802A (sh) Polimorfni oblik atorvastatin kalcijuma
BR9811099A (pt) Inibidores de urocinase
NO20020214D0 (no) Substituerte oksozaheterocyklylforbindelser
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
MX9702865A (es) Agentes estrogenicos.
NO20032254D0 (no) Forbindelser for inhibering av ekspresjon av VACM-I
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
UA29446C2 (uk) Засіб для інгібування тромбіну
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
EP1240280A4 (de) Behandlung von kohle
MXPA01006469A (es) Combinaciones de inhibidores de proteina de transferencia de ester colesterilico y derivados de acido fibrico para indicaciones cardiovasculares.
DK1001761T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsunderskudslidelser
DK1105114T3 (da) Nimesulidholdige topiske farmaceutiske sammensætninger
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties